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Objective: This study evaluates the correlation between closed, semi-closed and open-cell stent design
and the association between stent type and clinical outcome as well as magnetic resonance imaging
(MRI) ﬁndings.
Design: A total of 194 patients who underwent unprotected carotid artery stenting (CAS) as well as
diffusion-weighted magnetic resonance imaging (DW-MRI) before and after intervention were retro-
spectively reviewed.
Materials and methods: Three stent designs were studied: closed cell, semi-closed cell and open cell.
Spearman’s Rho test was performed between the stent free cell area and the number and area of
ischaemic lesions found after intervention. Adverse events were evaluated.
Results: There was no signiﬁcant difference in clinical outcome between the three stent groups (Zilver,
Cook Europe, Denmark; Smart, Codman, MA; and Wallstent, Stryker, MN, USA). A signiﬁcant correlation
was found between the stent free cell area and the number and area of new ischaemic lesions on DW-
MRI (P ¼ 0.023). There were signiﬁcantly fewer new lesions with an open-cell design (Zilver; 12.76 mm2
free cell area) than with a closed-cell design (Wallstent; 1.08 mm2 free cell area).
Conclusions: Open-cell stent was related to a lower number and area of silent cerebral ischaemic lesions
after unprotected CAS. However, clinical outcome, measured by incidence of adverse events and clinical
neurologic assessment, was not signiﬁcantly different between patients with different stent designs.
 2011 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.About 20% of all strokes are caused by atherosclerotic disease of
the carotid artery.1 In the past several years, cervicocerebral vessel
stent placement has emerged as a less-invasive therapeutic alter-
native to carotid endarterectomy (CEA) in patients with signiﬁcant
extracranial stenosis. The safety of internal carotid artery stenting
(CAS) has been demonstrated, and carotid stents have received US
Food and Drug Administration approval for use in high-risk
patients.26 Whilst publication of the International Carotid Stent-
ing Study (ICSS) cast doubt on whether stenting can be used as an
alternative to endarterectomy in selected patients, results of the
Carotid Revascularization Endarterectomy versus Stenting Trial
(CREST) were very encouraging and showed that the endovascular
approach for CAS is a valid treatment option.7).
Elsevier Ltd on behalf of EuropeanAdvancements in technology have made the treatment of
difﬁcult-to-approach stenoses feasible with CAS. With the variety
of stent designs available, it is often difﬁcult to decidewhich stent is
the most appropriate for a given lesion. There is an empiric
opinion8 that open-cell stent designs (a cell not totally enclosed by
its walls and hence interconnecting with other cells) are not suit-
able for ulcerate lesions and that closed-cell stents (totally
enclosed, no interconnection with other cells) cover the plaque
more effectively, leading to better results. Bosiers et al.8 supported
this opinion in a study that claimed higher late complication rates
in symptomatic patients using open-cell types and concluded that,
for the time being, consideration should be given to the use of
stents with a small free cell area, especially in symptomatic
patients. However, when transient ischaemic attacks were not
evaluated as ‘minor stroke’, Hart,8 using the same data, could not
observe any difference.Society for Vascular Surgery.
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patient outcome, the present retrospective study examined the
difference in outcome between closed, semi-closed (close cell mesh
that interconnects with other cells) and open-cell stent designs in
194 patients. Clinical outcome was measured by documentation of
a neurological evaluation and the incidence of adverse events.
Furthermore, to achieve an ‘objective’ evaluation of the devices,
cerebral diffusion-weighted magnetic resonance imaging (DW-




A retrospective review was conducted on a cohort of 194
patients, who were treated with unprotected CAS for carotid artery
stenosis between June 2000 and December 2006. Only patients
undergoing CAS without cerebral protection were included in this
study, as the use of these devices might inﬂuence the occurrence of
DWI lesions. Patients with symptomatic and asymptomatic stenosis
(70% according to North American Symptomatic Carotid Endarter-
ectomy Trial collaborators (NASCET) criteria) were included.10
Symptomatic patients were deﬁned as those with transient
ischaemic attack (TIA), minor stroke or major stroke in the vessel
dependent area within the last 4 weeks.
Indication to treat was established by an independent neurol-
ogist. All patients were offered preoperative discussions with
vascular surgeons and neuro-interventionalists. Patients were
informed about medical, surgical and interventional treatment
options and chose their treatment. Patients with intolerance to
aspirin or clopidogrel or known contrast allergy were excluded
from stent treatment.
Preoperative imaging was done using Doppler/duplex and
magnetic resonance (MR) angiography. The stenosis was then
conﬁrmed with digital subtraction angiography (DSA).
Stent placement
All patients received adjunctive drug therapy with acetylsali-
cylic acid (ASA), clopidogrel and low-molecular-weight heparin
before, during and after the procedure. In general, aspirin and
clopidogrel were started 3 days in advance and maintained for 6
weeks. CAS was performed by three interventionalists who had
experience with over 50 CAS procedures. More than 100 proce-
dures are performed annually in the centre. The stent placement
procedure was as follows: after diagnostic DSA and veriﬁcation of
the indication, a 6 F introductory sheath (Cordis, Cordis Corpora-
tion, Miami Lakes, FL, USA; Cook, Cook Europe, Bjaeverskov, Den-
mark; 90 cm length) was placed in the common carotid artery
(CCA). Then the stent was introduced using a 1400 microwire (e.g.,
Transcend hydrophilic-coated guide wire, Boston Scientiﬁc, Florida,Figure 1. Stent mesh design shUSA). After passing the stenosis with a microwire, the stent was
placed. Post-dilatation was routinely performed in all patients
using a 5- or 6-mm-diameter balloon. After removal of the device,
angiography was repeated to evaluate the adequacy of the CAS
procedure and any possible thrombus development. In addition,
the intracranial circulation was evaluated to assess the ﬂow
dynamics, vasospasm or the possibility of embolic phenomena.
Stent design
Carotid artery stents used in the procedures included a closed-
cell design (Wallstent, Boston Scientiﬁc, Minneapolis, MN, USA) in
36 cases; a semi-closed cell design (S.M.A.R.T. Nitinol Stent,
Cordis Corporation, Miami Lakes, FL, USA; or Cordis PreciseNitinol
Stent System, Cordis Corporation, Warren, NJ, USA) in 74 cases; and
an open-cell design (Zilver Vascular Stent, William Cook Europe,
Bjaeverskov, Denmark) in 84 cases. Stents were chosen based upon
availability, at the discretion of the operator. The free cell area of the
closed-cell Wallstent is about 1.08 mm2, the free cell area of the
semi-open-cell S.M.A.R.T. stent is about 5.89 mm2 and the free cell
area of the open-cell Zilver stent is about 12.76 mm2 (Fig. 1). The
information was provided by the manufacturers. The Cordis Pre-
cise stent is of intermediate construction, although many inter-
ventionists would argue that this stent, one of the earliest available
dedicated carotid stent systems, is a pure open-cell design, given its
cross-links.
Clinical evaluation
Major adverse events were deﬁned as any neurological deﬁcit
lasting for more than 24 h. A neurological examination was
completed by an experienced neurologist before and after the
intervention and on the day of discharge. Barthel scores and
modiﬁed Rankin Scale (MRS) scores were determined before and
after the intervention. All neurological changes, including TIA, were
recorded.
Imaging
All patients were evaluated on a 1.5T Siemens magnet with
cerebral DW-MRI before and after stent placement according to our
centre’s CAS protocol. Cerebral DW-MRI was performed at the
following time points. DWI was scheduled the day before and the
day after CAS.Whole-brain diffusion-weighted images (DWIs) were
acquired with an echo-planar sequence. An isotropic sequence was
used (repetition time: 4000 ms, echo time: 133 ms, ﬁeld of view:
210 mm, matrix: 128  128, and number of excitations: 4), with
b values of 0 and 972 s mm2. DWIs were evaluated by an experi-
enced neuroradiologist, blinded to the clinical status of the
patients. All new hyperintensities on the brain scans were evalu-
ated and categorised according to size, frequency and location.
Lesions located in the anterior territory of the stented side wereowing free cell area in red.
Table 1








Asymptomatic 7 (19.4%) 29 (39.2%) 25 (29.8%)
Symptomatic 29 (80.6%) 45 (60.8%) 59 (70.2%)
Age 66.5  1.4 67.6  0.9 68.9  1.0
Mean degree of stenosis
on stented side
86% 87.2% 87.7%
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vessel independent. Lesions were counted and then categorised by
size, as previously described17: 2 mm2, 2e5 mm2 and>5 mm2. This
was done for the stented and contralateral sides.
Statistical analysis
Statistical analyses were performed using SPSS (SPSS Inc., Chi-
cago, IL, USA). A Spearman’s Rho non-parametric correlation was
performed to determine whether there was a correlation between
the stent free cell area and the number or area of new ischaemic
lesions detected by DW-MRI after unprotected CAS. Signiﬁcance
was established at P < 0.05. Multivariate analysis included stent
design, gender, age, symptomatic and asymptomatic patients,
degree of stenosis on the stented and contralateral side, number
and area of lesions, medical risk factors as well as ﬂuoroscopy time.
Results
Clinical outcome
Clinical outcome of patients as measured by Barthel and MRS
score revealed no signiﬁcant difference between the three groups.
The Barthel Index, before and after intervention, in the closed-cell
group was 91.6 versus 92; in the semi-closed group, 90.6 versus
90.6; and in the open-cell group, 90.8 versus 91.8. The MRS score
before and after intervention in these three groups did not differ. In
addition, therewas no difference between the groups regarding the
distribution of the occurrence of major adverse events or the
incidence of TIA.
One patient from the open-cell group suffered hyperperfusion
syndrome with intracranial haemorrhage that led to death. There
was one patient in the open-cell group with a stroke, six patients
with TIAs and one patient with a minor stroke that completely
resolved on day 2. The total stroke-death rate was 1.03% (2/194).
Together with theminor, resolved stroke, the rate for complications
was 1.55% (3/194). Including TIAs, the rate for complications was
4.64% (9/194). One TIA occurred in the closed-cell group (2.8%), two
(2.7%), in the semi-closed group and three (3.6%) in the open-cell
group (Table 2).
Patient characteristics
A total of 194 patients (143 men, 51 women) were selected for
this analysis. The mean age of these patients was 68.0  0.6 years.Table 2







TIA 1 (2.8%) 2 (2.7%) 3 (3.6%)
PRIND 0 (0%) 1 (1.35%) 0 (0%)
Stroke 0 (0%) 0 (0%) 1 (1.2%)
Death 0 (0%) 0 (0%) 1 (1.2%)The mean degree of carotid artery stenosis on the dependent side
was 87%  0.7 as determined byNASCET9 criteria. The study
included 133 (68.6%) symptomatic patients and 61 (31.4%)
asymptomatic patients. Patient demographics are presented in
Table 1.
When comparing patient characteristics between the three
cohorts receiving the different stent designs, there was no
signiﬁcant difference. Distribution of symptomatic and asymp-
tomatic patients in the three groups was the same. In addition,
there was no difference in the mean degree of stenosis on the
stented side. In addition, there was no difference in the number of
patients with risk factors for diabetes, history of coronary/
peripheral arterial disease or hypercholesterolaemia. There was,
however, a tendency towards older patients in the open-cell
group, but this difference was not statistically signiﬁcant
(P ¼ 0.06). There were more smokers in the semi-closed-cell
group, and there were signiﬁcantly fewer hypertensives in the
closed-cell group (P ¼ 0.031).
Imaging results
There was a signiﬁcant correlation between the free cell area of
the different carotid stents and the number of new cerebral
ischaemic lesions detected by DW-MRI after stent placement,
P ¼ 0.027 (Fig. 2). There was also a signiﬁcant correlation between
the free cell area of the stents and the area of new cerebral
ischaemic lesions detected by DW-MRI, P ¼ 0.024 (Fig. 3). In both
cases, the correlation was inverse, that is, the larger the free cell
area, the fewer (or the smaller total area) new ischaemic lesions
were identiﬁed.
When using a stent with an open-cell design (Zilver, 12.76 mm2
free cell area), lesions seemed to occur less frequently (0.5 per
patient with Zilver vs. 1.5 per patient with Wallstent) thanwith the
closed-cell design (Wallstent, 1.08 mm2 free cell area), but this
difference lacked statistical signiﬁcance (P ¼ 0.089). The same
applied for the area of lesions (3.5 mm per patient with Zilver vs.
13.1 mm per patient with Wallstent, P ¼ 0.078). Again, the differ-
ence was not statistically signiﬁcant.
Discussion
Angioplasty with stent placement is increasingly used for the
treatment of severely stenotic carotid artery disease.11 New trials
(Stent-Protected Angioplasty in Asymptomatic Carotid ArteryFigure 2. Correlation between the free cell area and the number of lesions.
Figure 3. Correlation between the free cell area and the total area of lesions.
I.Q. Grunwald et al. / European Journal of Vascular and Endovascular Surgery 43 (2012) 10e14 13Stenosis versus Endarterectomy trial (SPACE 2) and Asymptomatic
Carotid Surgery Trial (ACST-2)) are currently evaluating asymp-
tomatic patients regarding beneﬁt of CAS in stroke prevention. As
the number and designs of available vascular stents increase,
clinicians must assess whether all stent designs are equally
effective for the treatment of arterial stenoses.12 There are only
few studies comparing open-cell with closed-cell design.8,13,14 In
one,8 it was concluded that closed-cell stent designs post-
procedurally cover carotid arterial lesions more effectively than
open-cell stent design. However, there are some major limitations
to this study. First, the study population is not homogeneous, as it
is a retrospective multicentre study over a long period of time,
during which therapy differs because delivery devices dramati-
cally improved over this time. In addition, there are a number of
different protection devices used including seven different distal
protection devices and two proximal protection devices. In seven
cases, no protection device was used, thus adding to the hetero-
geneity of the study. The authors mention that the learning curve
was excluded; however, they did not take into account the
learning curve for the protection devices, especially the distal
protection devices, where it is required to cross the lesion before
stenting. Further, the report claims that all patients were given
a standard anticoagulation regime, but only in recent years has
the inﬂuence of combined anti-platelet therapy been proven and
widely accepted. Finally, no DW-MRI was performed before or
after CAS. Therefore, small, clinically ‘silent’ thrombo-embolic
events during and after the procedure could not be detected. A
further study evaluated 1684 consecutive patients from 10 Euro-
pean centres who underwent CAS with either closed (n ¼ 859) or
open-cell (n ¼ 825) stent design. These data did not support the
superiority of a speciﬁc stent cell design with respect to neuro-
logic complications, stroke or mortality risk.12
In a rebuttal,13 it was suggested that regarding postprocedural
events (deﬁned as all neurological complications that occurred
after the removal of all endovascular material), there was a trend
towards a higher rate of late complications in the symptomatic
population for the open-cell group. However, as in our study, late
complications do not only comprise of emboli (allegedly caused
by embolisation through the open-cell structure) but also include
any neurological complication, for example, reperfusion
haemorrhage.
A non-randomised retrospective study including 132 carotid
stent procedures, although also underpowered for the clinical end
point, could also not ﬁnd a difference regarding clinical outcome or
stent patency among patients treated with open versus closed-celldesign at 2-year follow-up.14 However, contrary to our study,
patients were treated with and without ﬁlter protection.
The objective of the present study is to show results for a large
group of relatively homogeneous patients, comparing three stent
designs over a period of 5 and a half years. There is an empiric
opinion that open-cell stent designs are not suitable for ulcerate
lesions and that closed-cell stents cover the plaque more effec-
tively, thus preventing postprocedural embolisation through the
stent struts and leading to better clinical results. Since no protec-
tion devices were used in our study, as is the custom in many
neuro-interventional sites in Europe, they could not have pre-
vented or even contributed to the subsequent cerebral ischaemic
lesions identiﬁed. The major advantage of this study is that per-
forming DW-MRI before and after the procedure provides an
objective evaluation of the three stent designs. By using DW-MRI,
‘silent’ thrombo-embolic events, without clinical symptoms such
as stroke, could be detected after stent placement. Although the
impact of such lesions upon cognitive function is still
unknown,1518 they seem to be a good way to measure the
frequency of embolic events. All patients received adjunctive drug
therapy before and during the procedure (aspirin, clopidogrel and
low-molecular-weight heparin). Patient characteristics were not
signiﬁcantly different between the three groups with respect to
mean degree of stenosis, age and gender. Except for hypertension,
demographic analysis regarding smoking habits, diabetes, history
of coronary/peripheral artery disease and hypercholesterolaemia
did not differ signiﬁcantly between the groups. Patient age was
slightly higher in the open-cell stent group, which would seem to
bias the study away from favouring the open-cell design. The
present study demonstrates that stents with the closed-cell design
were associated with more cerebral ischaemic lesions than were
open-cell stent designs, as detected by postprocedure DW-MRI.
Since DW-MRI was performed after unprotected CAS in the ﬁrst
few postprocedural days, the occurrence of silent ischaemic lesions
in the 30-day period after stenting cannot be excluded. However,
no new neurological complications (death, major stroke or TIA)
occurred in the ipsilateral side at the time of follow-up. With the
low complication rate experienced, this study is underpowered for
differences in clinical event rate but not regarding DWI lesions. The
occurrence of a reperfusion haemorrhage with subsequent death in
the open-cell group can, in our opinion, not be attributed to the
stent design but was, nevertheless, included in the evaluation.
Readers should thus be cautious when interpreting trends in clin-
ical outcome.
Due to the retrospective nature of the present study, it is limited
by the fact that there was no randomisation of patients or devices.
These were chosen according to availability. There were no oper-
ator speciﬁc preferences. Open-cell stents (Zilver) were used
slightly more frequently in the years 2005 and 2006, whereas
Wallstents were mainly placed during 2001e2003. As CAS can be
inﬂuenced by vessel anatomy and complexity of the procedure, we
evaluated the ﬂuoroscopy time for each procedure as a marker for
complexity. There was no signiﬁcant difference between the three
stent groups and ﬂuoroscopy time was also part of the multivariate
analysis. Despite this, we cannot completely exclude an inﬂuence
on our results.
We think that our results are not relevantly inﬂuenced by the
interventionalists’ learning curve as CAS was already an accepted
alternative to CEA at this institution when these data were
collected. It has previously been suggested that plaque vulnera-
bility is higher with shorter time interval between event and
treatment in patients who undergo CEAwithin 4weeks to beyond 4
weeks from the last insult.19 In our study, patients were deﬁned as
symptomatic if stroke symptoms occurred within 1 month. All
symptomatic patients were started on dual anti-platelet therapy
I.Q. Grunwald et al. / European Journal of Vascular and Endovascular Surgery 43 (2012) 10e1414within 24 h to receive stenting on day 3 (often including
weekends).
Based on the results of this study, open-cell or semi-closed-cell
stent designs seem to cover the plaque sufﬁciently to prevent
clinically evident postprocedural embolisation through the stent
struts. In both the symptomatic and asymptomatic patient pop-
ulations, free cell area or cell type did not signiﬁcantly affect the
clinically detectable event rate, thus showing that cell size did not
inﬂuence event rate. It is unclear if a higher sample size would
eventually show signiﬁcance. It is possible that Bosiers et al.20 ob-
tained different results due to the use of different protection and
delivery devices. For example, it is the opinion of the authors that
the delivery system catheter of Zilver has a tapered and smoother
tip, which provides more ﬂexibility to follow the microwire easily
during the stent procedure. In addition, this tapered tip may enable
the delivery catheter to pass across tight stenoses better, and
reduce the possibility of disrupting existing plaques, compared
with other delivery catheters that have blunt ends. Therefore, the
results may be inﬂuenced by the type of delivery catheter. The
crossing proﬁle differences between the stents are highly relevant.
The Wallstent, a closed-cell design, by any deﬁnition, has a rather
cumbersome nose cone that has to be tracked through the lesion,
whilst the tapered leading point of the open-cell Cook Zilver is
wholly different. ‘Snow ploughing’ of the lesion is muchmore likely
with the Wallstent than the Zilver, particularly so as predilatation
was not routinely performed in our patients. Another possibility is
that higher numbers or more speciﬁc neurologic testing, including
tests on cognitive function, are necessary to reveal a signiﬁcant
difference in clinical outcome.21,22 A randomised trial would be
needed to determine differences in lesion load.
Open-cell stent design was related to fewer cerebral ischaemic
lesions detected by DW-MRI following CAS placement. However,
clinical outcome, measured by the incidence of adverse events and
clinical neurologic assessment, was not signiﬁcantly different
between patients with different stent designs.Acknowledgement
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